Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting
查看参考文献24篇
|
文摘
|
It is currently believed that triple oral antithrombotic therapy in patients with atrial fibrillation (AF) after percutaneous coronary intervention (PCI) should be recommended if there are no contraindications. However, selecting triple therapy for AF patients undergoing PCI is still challenging when bleeding risk is considered. This study aimed to investigate the current use of oral anticoagulants (Vitamin K antagonists [VKA]) and perform prognostic analysis in real-world patients with AF undergoing coronary stenting. Methods: A total of 276 consecutive coronary artery disease (CAD) patients with or without AF undergoing coronary stenting were retrospectively evaluated and analyzed. The univariate and multivariate analyses were conducted to explore the current use of VKA and prognosis of patients with AF undergoing coronary stenting. The primary end-point was composite of all-cause death, nonfatal recurrent myocardial infarction, stroke, serious bleeding events, unplanned repeat revascularization, and worsening heart failure at 12-month follow-up after coronary stenting. Results: AF patients undergoing coronary stenting have more clinical concomitant diseases. Only 9.0% AF patients after coronary stenting received triple antithrombotic therapy (VKA, aspirin, and clopidogrel) at discharge. AF was independently associated with increased risk of the 12-month composite end-points (relative risk = 5.732, 95% confidence interval 1.786-18.396,P = 0.003). Conclusions: In real-life AF patients undergoing coronary stenting, guideline-recommended VKA was less used. AF patients had adjusted worse prognosis during 12-month follow-up after discharge. It is of utmost importance to improve the current status of oral anticoagulants use. |
|
来源
|
Chinese Medical Journal
,2017,130(12):1418-1423 【核心库】
|
|
DOI
|
10.4103/0366-6999.207460
|
|
关键词
|
Antithrombotic Therapy
;
Atrial Fibrillation
;
Coronary Artery Disease
;
Percutaneous Coronary Intervention
;
Prognosis
|
|
地址
|
Department of Cardiology, The First Affiliated Hospital of Dalian Medical University, Liaoning, Dalian, 116011
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
0366-6999 |
|
学科
|
医药、卫生 |
|
基金
|
supported by grants from the Health and Family Planning Commission of Liaoning, China
;
the Science and Technology Program of Dalian, China
|
|
文献收藏号
|
CSCD:6009463
|
参考文献 共
24
共2页
|
|
1.
Cho J R. Percutaneous coronary intervention and atrial fibrillation:The triple therapy dilemma.
J Thromb Thrombolysis,2015,39:203-208
|
CSCD被引
2
次
|
|
|
|
|
2.
Kirchhof P. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Eur Heart J,2016,37:2893-2962
|
CSCD被引
188
次
|
|
|
|
|
3.
O'Gara P T. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
Circulation,2013,127:e362-e425
|
CSCD被引
77
次
|
|
|
|
|
4.
Almendro-Delia M. Prognostic impact of atrial fibrillation in acute coronary syndromes:Results from the ARIAM registry.
Eur Heart J Acute Cardiovasc Care,2014,3:141-148
|
CSCD被引
2
次
|
|
|
|
|
5.
Bramlage P. Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents.
Clin Res Cardiol,2013,102:289-297
|
CSCD被引
1
次
|
|
|
|
|
6.
Angeli F. Atrial fibrillation and mortality in patients with acute myocardial infarction:A systematic overview and meta-analysis.
Curr Cardiol Rep,2012,14:601-610
|
CSCD被引
3
次
|
|
|
|
|
7.
Rohla M. Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease.
Int J Cardiol,2015,184:108-114
|
CSCD被引
2
次
|
|
|
|
|
8.
Bai Y. Clinical characteristics and one year outcomes in Chinese atrial fibrillation patients with stable coronary artery disease: a population-based study.
J Geriatr Cardiol,2016,13:665-671
|
CSCD被引
1
次
|
|
|
|
|
9.
Soliman E Z. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction:The Atherosclerosis Risk in Communities (ARIC) Study.
Circulation,2015,131:1843-1850
|
CSCD被引
5
次
|
|
|
|
|
10.
Camm A J. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.
Eur Heart J,2012,33:2719-2747
|
CSCD被引
97
次
|
|
|
|
|
11.
Mehran R. Standardized bleeding definitions for cardiovascular clinical trials:A consensus report from the Bleeding Academic Research Consortium.
Circulation,2011,123:2736-2747
|
CSCD被引
141
次
|
|
|
|
|
12.
Kiviniemi T. Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Circ J,2014,78:2674-2681
|
CSCD被引
1
次
|
|
|
|
|
13.
Sambola A. Impact of triple therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention.
PLoS One,2016,11:e0147245
|
CSCD被引
2
次
|
|
|
|
|
14.
Pilgrim T. Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents.
Eurolntervention,2013,8:1061-1071
|
CSCD被引
3
次
|
|
|
|
|
15.
Dzeshka M S. Patients with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and concerns:Part I.
Pol Arch Med Wewn,2015,125:73-81
|
CSCD被引
2
次
|
|
|
|
|
16.
Faza N N. Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions.
Catheter Cardiovasc Interv,2017,89:E64-E74
|
CSCD被引
1
次
|
|
|
|
|
17.
Zalewski J. Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation.
Postepy Kardiol Interwencyjnej,2016,12:290-302
|
CSCD被引
2
次
|
|
|
|
|
18.
Elewa H. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting:Searching for the best combination.
Semin Thromb Hemost,2016,42:662-670
|
CSCD被引
1
次
|
|
|
|
|
19.
Hu D. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
J Am Coll Cardiol,2008,52:865-868
|
CSCD被引
37
次
|
|
|
|
|
20.
Lamberts M. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
J Am Coll Cardiol,2013,62:981-989
|
CSCD被引
14
次
|
|
|
|
|
了解气象卫星更多信息，请访问